Ribon Therapeutics is a clinical-stage biotechnology company developing therapeutics that target stress support pathways and novel enzyme families activated under cellular stress. Its pipeline includes two oral, potentially first-in-class clinical programs: RBN-2397, a PARP7 inhibitor for oncology, and RBN-3143, a PARP14 inhibitor for immunology and inflammatory diseases. The company leverages its proprietary BEACON+ platform to design selective small-molecule inhibitors of NAD+-utilizing enzymes, beginning with monoARTs. Ribon plans to use the $25 million equity investment from Pfizer to support clinical development of its lead programs. As part of the investment, Pfizer’s Robert Rickert joined Ribon’s Scientific Advisory Board and Ribon will work with Pfizer to leverage its global development expertise. Ribon will retain economic rights and control of clinical development across all its programs and is based in Cambridge, Massachusetts. Ribon Therapeutics is a clinical-stage biotechnology company developing small-molecule therapeutics that target stress support pathways implicated in cancer and inflammation. Its pipeline is built on a proprietary BEACON+ platform focused on selective inhibitors of NAD+-utilizing enzymes, beginning with monoPARPs. The company’s lead oncology program is RBN-2397 (a PARP7 inhibitor) and it also has RBN-3143 in development for inflammation. Ribon will use new financing to advance these lead programs through key clinical milestones and to support additional drug discovery and validation. The company is based in Cambridge, Massachusetts and positions its work as precision-medicine approaches for patients with limited therapeutic options. The announcement reflects continued investor support as Ribon advances clinical and preclinical programs. Ribon Therapeutics develops first-in-class therapeutics targeting enzyme families activated under cellular stress, with an initial focus on monoPARPs. The company has built an integrated discovery platform to interrogate monoPARPs and develop selective, small-molecule inhibitors to NAD+‑utilizing enzymes. Its lead program is advancing PARP7 inhibitors for cancer, beginning with squamous cell carcinoma of the lung. Ribon says the 12 distinct monoPARPs have applications across cancer, inflammatory diseases and neurodegenerative diseases, giving its approach broad utility. Proceeds from the recent financing will be used to advance lead programs into clinical testing, including small-molecule monoPARP inhibitors. Ribon is located in Lexington, Massachusetts.

Total raised

$155M

Funding rounds

3

Latest round

Equity

Latest activity

Jan 2023